Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review

Biological Research for Nursing

Volumn 11, Issue 1, 2009, Pages 81-97

  Adegbola, Maxine A ^a  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

Chronic; Genetics; Genomics; Literature review; Nurses; Pain; Sickle cell

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; MORPHINE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; UGT2B7 PROTEIN, HUMAN;

ADULT; CHRONIC DISEASE; ETHNOLOGY; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; MALE; METABOLISM; METHODOLOGY; NURSE ATTITUDE; PAIN; PHARMACOGENETICS; PHENOTYPE; REVIEW; RISK FACTOR; SEXUAL DEVELOPMENT; SICKLE CELL ANEMIA;

ADULT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; CATECHOL O-METHYLTRANSFERASE; CHRONIC DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MORPHINE; NURSE'S ROLE; PAIN; PHARMACOGENETICS; PHENOTYPE; RECEPTORS, OPIOID, MU; RISK FACTORS; SEX CHARACTERISTICS;

EID: 67949085164     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800409337154     Document Type: Review

References (140)

1. Andersen, G., Christrup, L., & Sjgren, P. (2003). Relationship among morphine metabolism, pain and side effects during long term treatment: An update. Journal of Pain & Symptom Management, 25, 74.
2. Andersen, G., Jensen, N., Christrup, L., Hansen, S.H., & Sjgren, P. (2002). Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliative Medicine, 16, 107-114.
3. Andersen, G., Sjgren, P., Hansen, S.H., Jensen, N., & Christrup, L. (2004). Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. European Journal of Pain (London, England). 8, 263-271.
4. Anie, K.A. (2005). Psychological complications in sickle cell disease. British Journal of Haematology, 129, 723-729.
5. Anie, K.A., & Green, J. (2006). Psychological therapies for sickle cell disease and pain. Cochrane Database of Systematic Reviews 2002 (Issue 2, Art. No.: CD001916). DOI: 10.1002/14651858.CD001916.
6. Anie, K.A., & Steptoe, A. (2003). Pain, mood and opioid medication use in sickle cell disease. Hematology Journal, 4, 71-73.
7. Anie, K.A., Steptoe, A., & Bevan, D.H. (2002). Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. British Journal of Health Psychology, 7, 331-344. (Pubitemid 34975967)
8. Ashley-Koch, A., Yang, Q., & Olney, R.S. (2000). Sickle hemoglobin (hb S) allele and sickle cell disease: A HuGE review. American Journal of Epidemiology, 151, 839-845.
9. Baker, K. (2005). Recent advances in the neurophysiology of chronic pain. Emergency Medicine Australasia: EMA, 17, 65-72.
10. Ballas, S.K. (1998). Sickle cell disease: Clinical management. Baillieres Clinical Haematology, 11, 185-214.
11. Ballas, S.K. (2002). Sickle cell anaemia. Drugs, 62, 1143-1172.
12. Ballas, S.K. (2005). Pain management of sickle cell disease. Hematologoy/Oncology Clinics of North America, 19, 785-802.
13. Ballas, S.K., & Lusardi, M. (2005). Hospital readmission for adult acute sickle cell painful episodes: Frequency, etiology, and prognostic significance. American Journal of Hematology, 79, 17-25.
14. Ballas, S., Barton, F.B., Waclawiw, M.A., Swerdlow, P., Eckman, J.R., Pegelow, C.H., et al. (2006). Hydroxyurea and sickle cell anemia: Effect on quality of life. Health and Quality of Life Outcomes, 4, 59.
15. Belfer, I., Wu, T., Kingman, A., Krishnaraju, R.K., Goldman, D., & Max, M.B. (2004). Candidate gene studies of human pain mechanisms: Methods for optimizing choice of polymorphisms and sample size. Anesthesiology, 100, 1562-1572.
16. Benjamin, L.J., Dampier, C., Jacox, A., Odesina, V., Phoenix, D., Shapiro, B., et al. (1999). Guideline for the management of acute and chronic pain in sickle-cell disease (APS Clinical Guidelines Series, No. 1 ed.). Glenview, IL: American Pain Society.
17. Bergman, S. (2005). Psychosocial aspects of chronic widespread pain and fibromyalgia. Disability & Rehabilitation, 27, 675-683.
18. Bernard, S., Neville, K.A., Nguyen, A.T., & Flockhart, D.A. (2006). Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications [Electronic version]. Oncologist, 11, 126-135.
19. Bernardes, S.F., Keogh, E., & Lima, M.L. (2008). Bridging the gap between pain and gender research: A selective literature review. European Journal of Pain, 12, 427-440.
20. Beyer, A., Koch, T., Schrder, H., Schulz, S., & Hllt, V. (2004). Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human 1/4-opioid receptor. Journal of Neurochemistry, 89, 553-560.
21. Bodhise, P.B., Dejoie, M., Brandon, Z., Simpkins, S., & Ballas, S.K. (2004). Non-pharmacologic management of sickle cell pain. Hematology, 9, 235-237.
22. Bond, C., LaForge, K.S., Tian, M., Melia, D., Zhang, S., Borg, L., et al. (1998). Single-nucleotide polymorphism in the human 1/4-opioid receptor gene alters beta-endorphin binding. Proceedings of the National Academy of Sciences of the United States of America, 95, 9608.
23. Brousseau, D.C., McCarver, D.G., Drendel, A.L., Divakaran, K., & Panepinto, J.A. (2007). The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. Journal of Pediatrics, 150, 623-626.
24. Bunn, F.H. (1997). Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine, 337, 762-769.
25. Cai, W.M., Nikoloff, D.M., Pan, R.M., De Leon, J., Fanti, P., Fairchild, M., et al. (2006). CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: Implications for clinical practice and genetic testing. Pharmacogenomics Journal, 6, 343-350.
26. Campbell, C.M., France, C.R., Robinson, M.E., Logan, H.L., Geffken, G.R., & Fillingim, R.B. (2008). Ethnic differences in the nociceptive flexion reflex (NFR). Pain, 134, 91-96.
27. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., et al. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine, 332, 1317-1322.
28. Chou, W., Wang, C., Liu, P., Liu, C., Tseng, C., & Jawan, B. (2006). Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology, 105, 334-337. (Pubitemid 44148178)
29. Chou, W., Yang, L., Lu, H., Ko, J., Wang, C., Lin, S., et al. (2006). Association of 1/4-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiologica Scandinavica, 50, 787-792. (Pubitemid 44034227)
30. Christensen, K., & Murray, J. (2007). What genome-wide association studies can do for medicine. New England Journal of Medicine, 356, 1094-1097.
31. Claster, S., & Vichinsky, E.P. (2003). Managing sickle cell disease. British Medical Journal, 327, 1151-1155.
32. Coffman, B.L., Rios, G.R., King, C.D., & Tephly, T.R. (1997). Human UGT2B7 catalyzes morphine glucuronidation. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 25, 1-4.
33. Comer, E.W. (1999). Effects of a cognitive behavioral group intervention on the reduction of depressive symptoms in individuals with sickle cell disease (Doctoral dissertation, University of North Carolina, Chapel Hill). UMI no. AAT 9914827.
34. Comer, E.W. (2004). Integrating the health and mental health needs of the chronically ill: A group for individuals with depression and sickle cell disease. Social Work in Health Care, 38, 57-76.
35. Comer, E.W., Meier, A., & Galinsky, M.J. (2004). Development of innovative group work practice using the intervention research paradigm. Social Work, 49, 250.
36. Compton, P., Geschwind, D., & Alacron, M. (2003). Association between human 1/4-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 121B, 76-82..
37. Craft, R.M. (2008). Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids. Experimental and Clinical Psychopharmacology, 16, 376-385.
38. Crowley, J., Oslin, D., Patkar, A., Gottheil, E., DeMaria, P., O'Brien, C., et al. (2003). A genetic association study of the 1/4-opioid receptor and severe opioid dependence. Psychiatric Genetics, 13, 169-173.
39. Dahmani, S., Dupont, H., Mantz, J., Desmonts, J.M., & Keita, H. (2001). Predictive factors of early morphine requirements in the post-anaesthesia care unit (PACU). British Journal of Anaesthesia, 87, 385-389.
40. Darbari, D., Minniti, C., Rana, S., & van den Anker, J. (2008). Pharmacogenetics of morphine: Potential implications in sickle cell disease. American Journal of Hematology, 82, 233-236.
41. Dersh, J., Polatin, P., & Gatchel, R. (2002). Chronic pain and psychopathology: Research findings and theoretical considerations. Psychomatic Medicine, 64, 773-786.
42. Desmeules, J.A., Piguet, V., Ehret, G.B., & Dayer, P. (2004). Pharmacogenetics, pharmacokinetics, and analgesia. In J. S. Mogil (Ed.), The genetics of pain: Progress in pain research and management (pp. 211-254). Seattle, WA: International Association for the Study of Pain.
43. Diatchenko, L., Slade, G.D., Nackley, A.G., Bhalang, K., Sigurdsson, A., Belfer, I., et al. (2005). Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Human Molecular Genetics, 14, 135-143.
44. Dunlop, R.J., & Bennett, K. (2006). Pain management for sickle cell disease. Cochrane Database of Systematic Reviews, (2, Art No: CD003350.).
45. Edwards, C.L., Scales, M.T., Loughlin, C., Bennett, G.G., Harris-Peterson, S., De Castro, L.M., et al. (2005). A brief review of the pathophysiology, associated pain, and psychosocial issues in sickle cell disease. International Journal of Behavioral Medicine, 12, 171-179.
46. Edwards, R.R. (2005). Individual differences in endogenous pain modulation as a risk factor for chronic pain. Neurology, 65, 437-443.
47. Edwards, R.R., Moric, M., Husfeldt, B., Buvanendran, A., & Ivankovich, O. (2005). Ethnic similarities and differences in the chronic pain experience: A comparison of African American, Hispanic, and White patients. Pain Medicine, 6, 88-98.
48. Elander, J., Lusher, J., Bevan, D., & Telfer, P. (2003). Pain management and symptoms of substance dependence among patients with sickle cell disease. Social Science and Medicine, 5, 1683-1696.
49. Fillingim, R.B. (2004). Social and environmental influences on pain: Implications for genetics. In J. Mogil (Ed.), The genetics of pain (pp. 283-303). Seattle, WA: IASP Press.
50. Fillingim, R.B., Kaplan, L., Staud, R., Ness, T.J., Glover, T.L., Campbell, C.M., et al. (2005). The A118G single nucleotide polymorphism of the 1/4-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. Journal of Pain, 6, 159-167.
51. Foulkes, T., & Wood, J.N. (2008). Pain genes. PLoS Genetics, 4, e100 0086.
52. Frenette, P.S., & Atweh, G.F. (2007). Sickle cell disease: Old discoveries, new concepts, and future promise [Electronic version]. Journal of Clinical Investigation, 117, 850-858.
53. Gaedigk, A., Bhathena, A., Ndjountch, L., Pearce, R.E., Abdel-Rahman, S.M., Alander, S.W., et al. (2005). Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics Journal, 5, 276-276.
54. Gaedigk, A., Bradford, D.L., Marcucci, K.A., & Leeder, J.S. (2002). Unique CYP2D6 activity distribution and genotype-phenotype discordance in Black Americans. Clinical Pharmacology and Therapeutics, 72, 76-89.
55. Gatchel, R. (2004). Comorbidity of chronic pain and mental health disorders: The biopsychosocial perspective. American Psychologist, 59, 795-805.
56. Geller, A.K., & O' Connor, M.K. (2008). The sickle cell crisis: A dilemma in pain relief. Mayo Clinic Proceedings, 83, 320-323.
57. Gerber, N., & Apseloff, G. (1993). Death from a morphine infusion during a sickle cell crisis. Journal of Pediatrics, 123, 322-325.
58. Green, C.R., Ndao-Brumblay, S.K., Nagrant, A.M., Baker, T.A., & Rothman, E. (2004). Race, age, and gender influences among clusters of African American and White patients with chronic pain. Journal of Pain, 5, 171-182.
59. Greenspan, J.D., Craft, R.M., LeResche, L., Arendt-Nielsen, L., Berkley, K.J., Fillingim, R.B., et al. (2007). Studying sex and gender differences in pain and analgesia: A consensus report. Pain, 132, S26 - S45.
60. Guttmacher, A.E., & Collins, F.S. (2004). Genomic medicine-A primer in genomic medicine: Articles from the New England Journal of Medicine. In A. E. Guttmacher, F. S. Collins, & J. Drazen (Eds.), Baltimore, MD: John Hopkins University press.
61. Haque, A., & Telfair, J. (2000). Socioeconomic distress and health status: The urban-rural dichotomy of services utilization for people with sickle cell disorder in North Carolina. Journal of Rural Health, 16, 43-55.
62. Hartl, D., & Jones, E.W. (2005). Genetics: Analysis of genes and genomes (6 th ed.). Sudbury, MA: Jones and Bartlett.
63. Herrick, J.B. (1910). Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine, 6, 517-521.
64. Hooten, W.M., Townsend, C.O., & Decker, P.A. (2007). Gender differences among patients with fibromyalgia undergoing multidisciplinary pain rehabilitation. Pain Medicine, 8, 624-632.
65. Houston-Yu, P., Rana, S.R., Beyer, B., & Castro, O. (2003). Frequent and prolonged hospitalizations: A risk factor for early mortality in sickle cell disease patients. American Journal of Hematology, 72, 201-203.
66. Im, E., Chee, W., Guevara, E., Liu, Y., Lim, H., Tsai, H., et al. (2007). Gender and ethnic differences in cancer pain experience: A multiethnic survey in the United States. Nursing Research, 56, 296-306.
67. Im, E., Wonshik, C., Guevara, E., Yi, L., Hyun-Ju, L., & Hsiu-Min, T. (2007). Gender and ethnicity: Are they influencing cancer pain ? Oncology Nursing Forum, 34, 479-479.
68. Jacob, E. (2001). Pain management in sickle cell disease. Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses, 2, 121-131.
69. Janicki, P., Schuler, G., Francis, D., Bohr, A., Gordin, V., Jarzembowski, T., et al. (2006). A genetic association study of the functional A118G polymorphism of the human 1/4-opioid receptor gene in patients with acute and chronic pain. Anesthesia & Analgesia, 103, 1011-1017.
70. Kim, H., Neubert, J.K., San Miguel, A., Xu, K., Krishnaraju, R.K., Iadarola, M.J., et al. (2004). Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain, 109, 488-496.
71. Klepstad, P., Rakvag, T.T., Kaasa, S., Holthe, M., Dale, O., Borchgrevink, P.C., et al. (2004). The 118 A > G polymorphism in the human 1/4-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiologica Scandinavica, 48, 1232-1239.
72. Kutlar, A. (2005). Sickle cell disease: A multigenic perspective of a single gene disorder. Hematology, 10, 92-99. (Pubitemid 41825700)
73. Lenoci, J. M., Telfair, J., Cecil, H., & Edwards, R. R. (2002). Self-care in adults with sickle cell disease. Western Journal of Nursing Research, 24, 228-244.
74. Ltsch, J., & Geisslinger, G. (2005). Are 1/4-opioid receptor polymorphisms important for clinical opioid therapy ? Trends in Molecular Medicine, 11, 82-89. (Pubitemid 40193487)
75. Ltsch, J., & Geisslinger, G. (2006). Relevance of frequent 1/4-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics Journal, 6, 200-210.
76. Ltsch, J., Skarke, C., Grosch, S., Darimont, J., Schmidt, J., & Geisslinger, G. (2002). The polymorphism A118G of the human 1/4-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics, 12, 3-9.
77. Ltsch, J., Skarke, C., Schmidt, H., Liefhold, J., & Geisslinger, G. (2002). Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clinical Pharmacology and Therapeutics, 72, 151-162.
78. Makis, A.C., Hatzimichael, E.C., & Stebbing, J. (2006). The genomics of new drugs in sickle cell disease. Pharmacogenomics, 7, 919-917.
79. Mantione, K.J., Goumon, Y., Esch, T., & Stefano, G.B. (2005). Morphine 6beta glucuronide: Fortuitous morphine metabolite or preferred peripheral regulatory opiate ? Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 11, MS43 - MS46.
80. Max, M.B. & Stewart, W.F. (2008). The molecular epidemiology of pain: A new discipline for drug discovery. Nature Reviews Drug Discovery, 7, 647-658.
81. Max, M.B., Tianxia, W., Atlas, S.J., Edwards, R.R., Haythornthwaite, J.A., Bollettino, A.F., et al. (2006). A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Molecular Pain, 2, 1-15.
82. McClish, D.K., Levenson, J.L., Penberthy, L.T., Roseff, S.D., Bovbjerg, V.E., Roberts, J.D., et al. (2006). Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES project. Journal of Women's Health, 15, 146-154.
83. McHugh, G., & Thoms, G. (2001). Living with chronic pain: The patient's perspective. Nursing Standard, 15, 33-37.
84. Meghani, S.H., & Gallagher, R.M. (2008). Disparity vs inequity: Toward reconceptualization of pain treatment disparities. Pain Medicine, 9, 614-623.
85. Micklos, D., & Freyer, G. (2003). DNA science: A first course (2 nd ed.). NY: Cold Spring Harbor Laboratory Press.
86. Midence, K., & Elander, J. (1996). Adjustment and coping in adults with sickle cell disease: An assessment of research evidence. British Journal of Health Psychology, 1, 95-111.
87. Mogil, J. (Ed.). (2004). The genetics of pain: Progress in pain research and management. Seattle, WA: International Association for the Study of Pain.
88. Mogil, J.S., & Devor, M. (2004). Introduction to pain genetics. In J. S. Mogil (Ed.), The genetics of pain (pp. 1-17). Seattle, WA: International Association for the Study of Pain.
89. Montaez, A., & Berland, D. (2002). First steps in quality improvement: A pilot program for the management of acute sickle cell pain. Journal of Clinical Outcomes Management, 9, 19-26.
90. Nadel, C., & Portadin, G. (1977). Sickle cell crises: Psychological factors associated with onset. New York State Journal of Medicine, 77, 1075-1078.
91. Nebert, D.W., & Menon, A.G. (2001). Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics Journal, 1, 19-22.
92. Newcombe, P. (2002). Pathophysiology of sickle cell disease crisis. Emergency Nurse, 9, 19.
93. Nietert, P.J., Silverstein, M.D., & Abboud, M.R. (2002). Sickle cell anaemia: Epidemiology and cost of illness. PharmacoEconomics, 20, 357-366.
94. Nussbaum, R., McInnes, R., & Willard, H. (2001). Thompson and Thompson genetics in medicine (6 th ed.). Philadelphia: W.B. Saunders Company.
95. Oertel, B., & Ltsch, J. (2008). Genetic mutations that prevent pain: Implications for future pain medication. Pharmacogenomics, 9, 179-194.
96. Okpala, I., Thomas, V., Westerdale, N., Jegede, T., Raj, K., Daley, S., et al. (2002). The comprehensive care of sickle cell disease. European Journal of Haematology, 68, 157-162.
97. Osborne, R., Joel, S., Trew, D., & Slevin, M. (1990). Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clinical Pharmacology and Therapeutics, 47, 12-19.
98. Osborne, R., Thompson, P., Joel, S., Trew, D., Patel, N., & Slevin, M. (1992). The analgesic activity of morphine-6-glucuronide. British Journal of Clinical Pharmacology, 34, 130-138.
99. Pack-Mabien, A., Labbe, E., Herbert, D., & Haynes, J.J. (2001). Nurses' attitudes and practices in sickle cell pain management. Applied Nursing Research, 14, 187-192.
100. Pearson, T., & Maniolo, T.A. (2008). How to interpret a genome-wide association study. JAMA: The Journal of the American Medical Association, 299, 1335-1344.
101. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H., et al. (1994). Mortality in sickle cell disease-Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
102. Rakvag, T., Klepstead, P., Baar, C., Kvam, T.-M., Dale, O., Kassa, S., et al. (2005). The Val158Met polymorphism of the human catechol-O- methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain, 116, 73-78.
103. Reed, W., & Vichinsky, E.P. (1998). New considerations in the treatment of sickle cell disease. Annual Review of Medicine, 49, 461-474.
104. Rosenblatt, A.B., & Mekhail, N.A. (2005). Management of pain in addicted/illicit and legal substance abusing patients. Pain Practice, 5, 2-10.
105. Ruehlman, L.S., Karoly, P., & Newton, C. (2005). Comparing the experiential and psychosocial dimensions of chronic pain in African Americans and Caucasians: Findings from a national community sample. Pain Medicine, 6, 49-60.
106. Sarlani, E., Garrett, P.H., Grace, E.G., & Greenspan, J.D. (2007). Temporal summation of pain characterized women but not men with temporomandibular disorders. Journal of Orofacial Pain, 21, 309-317.
107. Schneider, S., Randoll, D., & Buchner, M. (2006). Why do women have back pain more than men? A representative prevalence study in the Federal Republic of Germany. Clinical Journal of Pain, 22, 738-747.
108. Schubert, S. (2005). Sickle cell patients find pain relief: New home treatment model reduces hospital emergency visits, inpatient days. Infusion, 11, 23.
109. Åer1/2, O., Hrazdilov, O., Matalov, E., & Åev?k, P. (2005). Pain research update from a genetic point of view. Pain Practice, 5, 341-348.
110. Shapiro, B.S., Benjamin, L.J., Payne, R., & Heidrich, G. (1997). Sickle cell-related pain: Perceptions of medical practitioners. Journal of Pain and Symptom Management, 14, 168-174.
111. Skorpen, F., & Laugsand, E.A. (2008). Variable response to opioid treatment: Any genetic predictors within sight ? Palliative Medicine, 22, 310-327.
112. Slade, G.D., Diatchenko, L., Bhalang, K., Sigurdsson, A., Fillingim, R.B., Belfer, I., et al. (2007). Influence of psychological factors on risk of temporomandibular disorders. Journal of Dental Research, 86, 1120-1125.
113. Smith, W.R., Bovbjerg, V.E., Penberthy, L.I., McClish, D.K., Levenson, J.L., Roberts, J.D., et al. (2005). Understanding pain and improving management of sickle cell disease: The PiSCES study. Journal of the National Medical Association, 97, 183-193.
114. Smith, W.R., Penberthy, L.T., Bovbjerg, V.E., McClish, D.K., Roberts, J.D., Dahman, B., et al. (2008). Daily assessment of pain in adults with sickle cell disease. Annals of Internal Medicine, 148, 94-101.
115. Somerville, M. (2004). Ethics and the genetics of pain. In J. Mogil (Ed.), The genetics of pain (pp. 321-337). Seattle, WA: International Association for the Study of Pain.
116. Somogyi, A.A., Barratt, D.T., & Coller, J.K. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81, 429-444.
117. Stain-Texier, F., Boschi, G., Sandouk, P., & Scherrmann, J.M. (1999). Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. British Journal of Pharmacology, 128, 917-924.
118. Stamer, U.M., & Stuber, F. (2007). Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology, 20, 478-484.
119. Stamer, U.M., Lehnen, K., Hthker, F., Bayerer, B., Wolf, S., Hoeft, A., et al. (2003). Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain, 105, 231.
120. Steinberg, M.H. (1999). Management of sickle cell disease. New England Journal of Medicine, 340, 1021.
121. Steinberg, M.H., & Brugnara, C. (2003). Pathophysiologicalbased approaches to treatment of sickle cell disease. Annual Review of Medicine, 54, 89-112. (Pubitemid 37390845)
122. Strickland, O.L., Jackson, G., Gilead, M., McGuire, D.B., & Quarles, S. (2001). Use of focus groups for pain and quality of life assessment in adults with sickle cell disease. Journal of National Black Nurses' Association, 12, 36-43.
123. Tait, R.C., & Chibnall, J.T. (1997). Physicians judgements of chronic pain patients. Social Science Medicine, 45, 1199-1205.
124. Thomas, J., & Barton, M. (2005). Self-hypnosis and sickle cell disease in children: Impact on disease. Journal of Developmental and Behavioral Pediatrics, 26, 466.
125. Thomas, V.J. (2000). Cognitive behavioural therapy in pain management for sickle cell disease. International Journal of Palliative Nursing, 6, 434-442.
126. Thomas, V.J., Dixon, A.L., & Milligan, P. (1999). Cognitive-behaviour therapy for the management of sickle cell disease pain: An evaluation of a community-based intervention. British Journal of Health Psychology, 4, 209-229.
127. Thomas, V.J., Gruen, R., & Shu, S. (2001). Cognitive behavioural therapy for the management of sickle cell disease pain: Identification and assessment of costs. Ethnicity and Health, 6, 59-67.
128. Thomas, V.J., & Taylor, L.M. (2002). The psychosocial experience of people with sickle cell disease and its impact on quality of life: Qualitative findings from focus groups. British Journal of Health Psychology, 7, 345-363.
129. Todd, K.H. (2005). Chronic pain and aberrant drug-related behavior in the emergency department. Journal of Law, Medicine & Ethics, 33, 761-769.
130. Todd, K.H., Green, C., Bonham, V.L. Jr., Haywood, C. Jr., & Ivy, E. (2006). Sickle cell disease related pain: Crisis and conflict. Journal of Pain, 7, 453-458.
131. Uhl, G., Sora, I., & Wang, Z. (1999). The 1/4-opiate receptor as a candidate gene for pain: Polymorphsms, variations in expression, nociception, and opiate responses. Proceedings of the National Academy of Sciences of the United States of America, 99, 7752-7755.
132. Vallerand, A.H., Hasenau, S., Templin, T., & Collins-Bohler, D. (2005). Disparities between black and white patients with cancer pain: The effect of perception of control over pain. Pain Medicine, 6, 242-250.
133. van Ryn, M., & Fu, S.S. (2003). Paved with good intentions: Do public health and human service providers contribute to racial/ethnic disparities in health? American Journal of Public Health, 93, 248-255.
134. von Knorring, L. (1989). The pathogenesis of chronic pain syndromes. Nordisk Psykiatrisk Tidsskrift, 43, 35-41.
135. Vukmir, R.B. (2004). Drug seeking behavior. American Journal of Drug & Alcohol Abuse, 30, 551-575.
136. Weisse, C.S., Foster, K.K., & Fisher, E.A. (2005). The influence of experimenter gender and race on pain reporting: Does racial or gender concordance matter ? Pain Medicine, 6, 80-87.
137. Weissman, D.E., & Haddox, D.J. (1989). Opioid pseudoaddiction -An iatrogenic syndrome. Pain, 36, 363-366.
138. Westerdale, N., & Jegede, T. (2004). Managing the problem of pain in adolescents with sickle cell disease. Professional Nurse, 19, 402-405.
139. Woods, K., Karrison, T., Koshy, M., Patel, A., Friedman, P., & Cassel, C. (1997). Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Reports, 112, 44-51.
140. Zubieta, J., Heitzeg, M.M., Smith, Y.R., Bueller, J.A., Xu, K., Xu, Y., et al. (2003). COMT val158met genotype affects 1/4-opioid neurotransmitter responses to a pain stressor. Science, 299, 1240-1243.